CVS Health study highlights GLP-1 benefits and the affordability challenge

Rhea-AI Summary

CVS Health (CVS) released research linking GLP-1 use to better health outcomes, but not overall cost savings at current prices.

The analysis used anonymized claims from commercially fully insured Aetna members, with index years from 2023 through 2025 and up to three years of follow-up. Compared with matched non-users, GLP-1 users had lower hospital use and medical spending, but those savings did not fully offset higher pharmacy spending. CVS Health's modeling suggests a net price of approximately $350 per month over three years would balance pharmacy spending and observed medical savings across the study population. The break-even point varies with patients' clinical risk, treatment duration and medication adherence.

Key Figures

Modeled net-price break-even: approximately $350 per month Adults medically eligible for semaglutide: more than 137 million

Modeled net-price break-even

approximately $350 per month

Over three years, pharmacy spending and observed medical savings would balance

Adults medically eligible for semaglutide

more than 137 million

U.S. adults across indications; some qualify under multiple indications

Key Terms

glp-1, medication adherence, break-even

3 terms

glp-1 medical

"CVS Health researchers found GLP-1 use was associated with better clinical outcomes"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

medication adherence medical

"a standard measure of medication adherence"

Medication adherence is how consistently patients take a prescribed drug the right way—correct dose, at the right times, and for the full recommended period. It matters to investors because real-world use determines a therapy’s effectiveness, market demand, payer coverage and long-term sales; poor adherence can make a drug look less effective than in trials, like not following a recipe and getting a different result than expected.

break-even financial

"The break-even point varies based on factors including patients' underlying clinical risk"

The point at which a business, project, product line, or activity generates enough revenue to exactly cover the costs associated with it, so profit (net income) is zero. It can be expressed as a sales amount in dollars or as a number of units and is calculated by separating fixed costs from variable costs and finding the sales level where total revenue equals total costs; some analyses distinguish accounting break-even (net income = 0) from cash or operating break-even (cash flow or operating profit = 0).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Real-world analysis finds better outcomes and lower medical spending, but current prices limit the full economic value

WOONSOCKET, R.I., Nov. 15, 2026 /PRNewswire/ -- CVS Health today released new research grounded in real-world data that puts numbers behind a central question facing employers and health plans as GLP-1 use grows: Do the medicines save enough elsewhere in the health care system to offset their cost?

The answer, at current prices, is not yet.

Using anonymized Aetna claims data from commercial fully insured members, CVS Health researchers found GLP-1 use was associated with better clinical outcomes, lower hospital use and lower medical spending compared with matched non-users. At current prices, those medical savings did not fully offset increased pharmacy spending.

"GLP-1s are remarkably effective medicines, and the health benefits are real. The challenge is making those benefits affordable at scale," said Amy Compton-Phillips, M.D. "That means getting treatment to the people most likely to benefit, helping them stay on therapy and bringing the price to a level that supports broader access."

The study examined commercial fully insured Aetna members who used GLP-1s, with index years from 2023 through 2025 and up to three years of follow-up. Researchers matched GLP-1 users with similar non-users based on factors including age, existing health conditions, prior health care use and medical and pharmacy spending.

Modeling from this study suggests that, across the study population, a net price of approximately $350 per month over three years would bring pharmacy spending and observed medical savings into balance. The break-even point varies based on factors including patients' underlying clinical risk, how long they remain on treatment and how consistently they take their medication.

Researchers also examined whether staying on treatment mattered, comparing all people who started a GLP-1 with those whose prescriptions covered at least 80% of days during follow-up, a standard measure of medication adherence.

The findings point to three conditions for getting more value from GLP-1s:

• Treat the right patients, prioritizing people most likely to benefit based on clinical evidence and individual need.
• Help people stay on therapy long enough to realize the health benefits.
• Lower the price so that improved health outcomes can translate into more sustainable access and overall costs.

The affordability question is becoming more urgent as the clinical reach of GLP-1 therapies expands. Originally developed for type 2 diabetes, the medicines now have approved uses across obesity and cardiovascular, liver and kidney disease. The white paper notes that more than 137 million U.S. adults are medically eligible for semaglutide across indications, with many qualifying under more than one.

The analysis does not suggest that financial break-even should be the sole measure of a medicine's value. It does show why price matters for employers and health plans trying to expand access to a highly effective class of drugs without adding unsustainable cost to the health care system.

Dr. Amy Compton-Phillips will be speaking on this topic later this afternoon at the HLTH industry conference in Las Vegas. The full CVS Health white paper, "GLP-1s: Good Drugs, High Prices," is available at https://www.cvshealth.com/content/dam/enterprise/cvs-enterprise/pdfs/2026/GLP1_Whitepaper.pdf

About CVS Health

CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of September 30, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated 37 million people through a broad range of health insurance products and related services. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Media contact

Ethan Slavin
860-273-6095
Ethan.Slavin@CVSHealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cvs-health-study-highlights-glp-1-benefits-and-the-affordability-challenge-302939570.html

SOURCE CVS Health

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CVS Health's GLP-1 study find about health outcomes and costs?

GLP-1 use was associated with better clinical outcomes, lower hospital use and lower medical spending compared with matched non-users. At current prices, however, the medical savings did not fully offset increased pharmacy spending.

What GLP-1 price did CVS Health estimate would balance pharmacy spending and medical savings?

CVS Health's modeling suggests a net price of approximately $350 per month over three years would balance pharmacy spending and observed medical savings across the study population. That break-even point varies with underlying clinical risk, time on treatment and how consistently patients take their medication.

How did CVS Health match patients in its GLP-1 study and assess medication adherence?

Researchers matched GLP-1 users with similar non-users using factors including age, existing health conditions, prior health care use, and medical and pharmacy spending. They also compared all GLP-1 starters with patients whose prescriptions covered at least 80% of days during follow-up, a measure of medication adherence.